2024 World Conference on Lung Cancer (WCLC) - ePosters-EP.08F.14 Outcomes of Durvalumab Consolidation Treatment in Stage III Unresectable NSCLC: A Retrospective Real-World Study

EP.08F.14 Outcomes of Durvalumab Consolidation Treatment in Stage III Unresectable NSCLC: A Retrospective Real-World Study

Back to course

Pdf Summary

This retrospective real-world study evaluates the effectiveness of durvalumab consolidation treatment in patients with Stage III unresectable non-small cell lung cancer (NSCLC), based on data from 96 individuals who underwent concurrent or sequential chemoradiotherapy (CRT) followed by durvalumab between 2018 and 2022. The study aimed to assess progression-free survival (PFS) and overall survival (OS) and used the Cox regression model to analyze the differences in these outcomes based on multiple variables including age, PD-L1 status, histological type, gender, time to durvalumab initiation, and type of radiation therapy.<br /><br />Key findings include:<br /><br />- At the analysis time, 62 out of 96 patients were alive.<br />- The median time from CRT to the start of durvalumab was 39 days.<br />- At a median follow-up of 22 months, the median PFS was 35 months, with 1-year and 2-year PFS rates of 64% and 55%, respectively.<br />- The median OS was 52 months, with 1-year and 2-year OS rates of 85% and 62%.<br />- The 5-year OS rate was 49.6%.<br />- Better survival rates were linked to patients with a PD-L1 status of 50% or higher, those who received concurrent chemoradiotherapy, and those who experienced immune-related adverse events.<br /><br />The study's outcomes align with other real-world studies and exceed those observed in the PACIFIC trial, highlighting the survival benefits of durvalumab consolidation therapy in this patient population. The findings suggest that certain factors, such as higher PD-L1 status and the occurrence of immune-related adverse events, are associated with improved survival outcomes.

Asset Subtitle

Marko Jakopovic

Meta Tag

Speaker Marko Jakopovic

Topic Local-Regional Non-small Cell Lung Cancer

Keywords

durvalumab

Stage III NSCLC

consolidation treatment

chemoradiotherapy

progression-free survival

overall survival

PD-L1 status

immune-related adverse events

real-world study

Cox regression model